​

Cardio Diagnostics Stock (NASDAQ:CDIO)

RevenueOwnershipFinancialsChart
Cardio Diagnostics by TradingView

Previous Close

$3.70

52W Range

$2.42 - $42.60

50D Avg

$3.74

200D Avg

$6.01

Market Cap

$6.70M

Avg Vol (3M)

$35.67K

Beta

2.87

Div Yield

-

CDIO Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Jan 14, 2022

Website

CDIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceMar 25
Reportable Segments$940.00

Fiscal year ends in Dec 24 | Currency in USD

CDIO Financial Summary

Dec 24Dec 23Dec 22
Revenue$2.02K$17.07K$950.00
Operating Income$-8.38M$-7.24M$-4.55M
Net Income-$-8.38M$-4.66M
EBITDA-$-1.53M$-4.64M
Basic EPS-$-0.66$-1.51
Diluted EPS-$-0.66$-1.51

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
RADXRadiopharm Theranostics Limited
CELZCreative Medical Technology Holdings, Inc.
ADXNAddex Therapeutics Ltd
NRSNNeuroSense Therapeutics Ltd.
ADILAdial Pharmaceuticals, Inc.
BCLIBrainstorm Cell Therapeutics Inc.
BCDABioCardia, Inc.
TCRTAlaunos Therapeutics, Inc.